Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 01 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-0.12 Insider Own4.05% Shs Outstand232.14M Perf Week8.68%
Market Cap1.10B Forward P/E- EPS next Y-0.24 Insider Trans-1.61% Shs Float222.73M Perf Month20.81%
Income-26.57M PEG- EPS next Q-0.10 Inst Own54.23% Short Float / Ratio17.12% / 5.75 Perf Quarter-1.24%
Sales134.27M P/S8.23 EPS this Y28.73% Inst Trans56.04% Short Interest38.12M Perf Half Y35.23%
Book/sh0.82 P/B5.78 EPS next Y19.60% ROA-12.24% Target Price9.58 Perf Year176.74%
Cash/sh0.71 P/C6.69 EPS next 5Y30.00% ROE-20.60% 52W Range1.68 - 5.12 Perf YTD67.02%
Dividend- P/FCF- EPS past 5Y20.81% ROI-12.01% 52W High-7.12% Beta1.04
Dividend %- Quick Ratio5.35 Sales past 5Y100.41% Gross Margin85.41% 52W Low183.33% ATR0.25
Employees133 Current Ratio5.54 Sales Q/Q1030.99% Oper. Margin-17.24% RSI (14)66.35 Volatility5.41% 5.65%
OptionableYes Debt/Eq0.18 EPS Q/Q120.98% Profit Margin-19.79% Rel Volume0.74 Prev Close4.51
ShortableYes LT Debt/Eq0.16 EarningsOct 31 BMO Payout- Avg Volume6.62M Price4.76
Recom1.00 SMA2016.52% SMA5021.87% SMA20021.21% Volume4,906,677 Change5.54%
Date Action Analyst Rating Change Price Target Change
Sep-07-23Initiated H.C. Wainwright Buy $9
Aug-25-23Upgrade Cantor Fitzgerald Neutral → Overweight $5 → $10
Mar-03-23Upgrade Wedbush Neutral → Outperform $3 → $6
Nov-17-22Upgrade Piper Sandler Neutral → Overweight $3 → $8
May-06-22Downgrade Cantor Fitzgerald Overweight → Neutral $7 → $1
Dec-01-21Upgrade Ladenburg Thalmann Neutral → Buy $6
Oct-14-21Downgrade Ladenburg Thalmann Buy → Neutral
Jul-21-21Downgrade Jefferies Buy → Hold $11 → $2
Jul-20-21Downgrade Wedbush Outperform → Neutral $3
Jul-20-21Downgrade Piper Sandler Overweight → Neutral $14 → $4
Nov-21-23 04:02PM
Nov-17-23 09:00AM
Nov-15-23 04:02PM
04:02PM Loading…
Nov-13-23 04:02PM
Nov-10-23 08:05AM
Nov-06-23 08:00AM
Nov-03-23 08:00AM
Nov-02-23 09:40AM
Nov-01-23 10:42AM
Oct-31-23 11:15PM
07:00AM Loading…
Oct-30-23 05:42PM
Oct-23-23 08:07AM
Oct-19-23 10:21AM
Oct-18-23 04:31PM
Oct-17-23 07:24PM
Oct-13-23 08:00AM
Oct-11-23 04:17PM
Oct-04-23 08:00AM
Sep-28-23 08:02AM
04:15AM Loading…
Sep-25-23 04:15AM
Sep-17-23 10:54AM
Sep-12-23 09:12AM
Sep-11-23 08:00AM
Sep-08-23 08:00AM
Sep-07-23 08:00AM
Sep-06-23 12:36PM
Aug-30-23 01:02PM
Aug-28-23 10:22AM
Aug-26-23 03:17PM
Aug-25-23 09:42AM
Aug-24-23 11:05AM
Aug-17-23 09:31AM
Aug-07-23 02:34PM
Aug-04-23 08:29AM
Aug-03-23 08:26AM
Aug-02-23 08:35AM
Jul-27-23 04:05PM
Jul-26-23 07:55AM
Jul-20-23 04:05PM
Jul-16-23 09:37AM
Jul-13-23 08:00AM
Jun-29-23 04:09PM
Jun-19-23 08:00AM
Jun-08-23 09:48AM
Jun-05-23 08:00AM
May-31-23 08:00AM
May-23-23 04:05PM
May-22-23 03:30PM
May-17-23 07:30AM
May-15-23 04:05PM
May-09-23 08:00AM
May-06-23 10:08AM
May-05-23 08:28AM
May-04-23 09:52AM
May-03-23 05:15PM
May-01-23 08:00AM
Apr-26-23 08:00AM
Apr-18-23 08:00AM
Apr-17-23 08:50AM
Apr-13-23 04:05PM
Apr-12-23 04:05PM
Apr-11-23 08:29AM
Apr-07-23 07:30AM
Mar-30-23 05:22PM
Mar-28-23 03:57PM
Mar-17-23 06:15PM
Mar-13-23 06:30AM
Mar-08-23 02:50PM
Mar-04-23 07:02AM
Mar-03-23 03:34PM
Mar-02-23 05:25PM
Feb-28-23 08:00AM
Feb-27-23 08:15AM
Feb-23-23 08:00AM
Feb-22-23 06:15PM
Feb-20-23 09:40AM
Feb-19-23 02:05PM
Feb-17-23 06:30AM
Feb-15-23 06:15PM
Feb-12-23 10:56AM
Feb-09-23 06:15PM
Ardelyx, Inc. is a biopharmaceutical company. It engages in the research, development, and commercialization of medicine for the treatment of cardiorenal diseases. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rosenbaum David P.Chief Development OfficerNov 30Sale4.503,00013,500359,543Dec 01 04:47 PM
RAAB MICHAELPresident & CEONov 20Sale4.3611,36849,589867,868Nov 22 05:19 PM
Rodriguez SusanChief Commercial OfficerNov 20Sale4.364,71420,563346,973Nov 22 05:20 PM
Renz Justin AChief Financial OfficerNov 20Sale4.362,87312,533332,426Nov 22 05:20 PM
Blanks RobertSee RemarksNov 20Sale4.362,83512,367260,453Nov 22 05:17 PM
Rosenbaum David P.Chief Development OfficerNov 20Sale4.362,83512,367362,543Nov 22 05:21 PM
Williams Laura AChief Medical OfficerNov 20Sale4.362,58111,259266,191Nov 22 05:22 PM
GRAMMER ELIZABETH ASee RemarksNov 20Sale4.362,38410,399325,675Nov 22 05:19 PM
Felsch Robert OraSee RemarksNov 20Sale4.361,0444,554117,066Nov 22 05:18 PM
Rosenbaum David P.Chief Development OfficerNov 20Sale4.369324,066113,293Nov 22 05:21 PM
Williams Laura AChief Medical OfficerNov 15Sale4.0025,00099,998266,839Nov 17 05:30 PM
Rosenbaum David P.Chief Development OfficerOct 10Sale4.001,6446,576365,378Oct 12 05:09 PM
Rosenbaum David P.Chief Development OfficerSep 08Sale4.552,89713,181367,022Sep 12 05:24 PM
RAAB MICHAELPresident & CEOAug 21Sale3.5511,41940,558876,236Aug 23 04:41 PM
Rodriguez SusanChief Commercial OfficerAug 21Sale3.554,73316,811348,687Aug 23 04:48 PM
Renz Justin AChief Financial OfficerAug 21Sale3.552,88410,243333,849Aug 23 04:42 PM
Rosenbaum David P.Chief Development OfficerAug 21Sale3.552,84610,108369,919Aug 23 04:45 PM
Blanks RobertSee RemarksAug 21Sale3.552,84610,108263,288Aug 23 04:36 PM
Williams Laura AChief Medical OfficerAug 21Sale3.552,5919,203291,839Aug 23 04:46 PM
GRAMMER ELIZABETH ASee RemarksAug 21Sale3.552,3928,496328,059Aug 23 04:39 PM
Felsch Robert OraSee RemarksAug 21Sale3.551,0483,722115,110Aug 23 04:38 PM
Rosenbaum David P.Chief Development OfficerAug 21Sale3.559373,328111,225Aug 23 04:45 PM
Williams Laura AChief Medical OfficerJun 27Sale3.3525,00083,632294,430Jun 29 07:22 PM
Blanks RobertSee RemarksJun 23Option Exercise3.4233,333113,999299,467Jun 27 06:40 PM
Blanks RobertSee RemarksJun 23Sale3.6333,333121,042266,134Jun 27 06:40 PM
RAAB MICHAELPresident & CEOMay 23Sale3.6511,35741,489887,655May 25 08:55 AM
Rodriguez SusanChief Commercial OfficerMay 23Sale3.654,71117,210353,420May 25 08:52 AM
Renz Justin AChief Financial OfficerMay 23Sale3.652,87310,496336,733May 25 08:53 AM
Rosenbaum David P.Chief Development OfficerMay 23Sale3.652,83510,357372,765May 25 08:52 AM
Blanks RobertSee RemarksMay 23Sale3.652,83510,357266,134May 25 08:54 AM
Williams Laura AChief Medical OfficerMay 23Sale3.652,5839,436319,430May 25 08:51 AM
GRAMMER ELIZABETH ASee RemarksMay 23Sale3.652,3848,709330,451May 25 08:54 AM
Felsch Robert OraSee RemarksMay 23Sale3.651,0463,821116,158May 25 08:55 AM
Rosenbaum David P.Chief Development OfficerMay 23Sale3.659343,412112,162May 25 08:52 AM
Rosenbaum David P.Chief Development OfficerMar 29Sale4.633,00013,888113,096Mar 31 06:50 PM
RAAB MICHAELPresident & CEOFeb 21Sale3.0013,44940,360896,012Feb 24 05:39 PM
Rodriguez SusanChief Commercial OfficerFeb 21Sale3.005,58616,764355,131Mar 02 04:36 PM
Renz Justin AChief Financial OfficerFeb 21Sale3.003,43910,320336,606Feb 24 05:37 PM
Rosenbaum David P.Chief Development OfficerFeb 21Sale3.003,39410,185375,600Feb 24 05:36 PM
Blanks RobertSee RemarksFeb 21Sale3.003,39410,185268,969Feb 24 05:40 PM
Felsch Robert OraSee RemarksFeb 21Sale3.003,2149,645114,204Feb 24 05:38 PM
Williams Laura AChief Medical OfficerFeb 21Sale3.003,1879,564319,013Feb 24 05:41 PM
GRAMMER ELIZABETH ASee RemarksFeb 21Sale3.002,9148,745329,954Feb 24 05:39 PM
Rosenbaum David P.Chief Development OfficerFeb 21Sale3.001,1143,343113,096Feb 24 05:36 PM